Log In
Thursday 24th May 2018

Bone marrow disease drug gets a no

4th March 2010

The National Institute for Health and Clinical Excellence (NICE) has decided that a drug for treating rare blood cancers will not be made available through the NHS in England and Wales.

Cancer charities say they are angered and disappointed by the NICE decision not to recommend azacitidine or Vidaza for treating myelodysplastic syndromes because it is too costly. Around four in 100,000 people in the UK suffer from MDS, a debilitating bone marrow disease which means the bone marrow does not produce enough of one or more types of blood cells.


Share this page


There are no comments for this article, be the first to comment!

Post your comment

Only registered users can comment. Fill in your e-mail address for quick registration.

Your email address:

Your comment will be checked by a Healthcare Today moderator before it is published on the site.

Mayden - Innovative cloud-based applications for healthcare
© Mayden Foundation 2018